Subscribe

Dis-Chem Pharmacies Limited (DCP.JO)

ZAc3,238.00 -12.00 (-0.37%)
ZA JNB Healthcare Medical - Pharmaceuticals
Address 23 Stag Road 1685
Midrand, GT, ZA
CEO Rui Manuel Morais
Website dischemgroup.com
IPO 2016-11-18
ISIN ZAE000227831

Explore sections of this company profile

Description

Dis-Chem Pharmacies Limited (DCP.JO) is a leading South African enterprise engaged in both the retail and wholesale supply of healthcare products and pharmaceuticals. The company operates through two distinct segments: Retail and Wholesale. Its extensive retail network encompasses numerous stores that provide a wide array of offerings, including dispensary services, personal care and beauty products, health and nutrition items, and baby essentials. These outlets further enhance their customer experience by offering ancillary services like healthcare clinics and hair and beauty salons. Dis-Chem also maintains an online platform that facilitates convenient click & collect services for its customers. On the wholesale front, the company handles the distribution of pharmaceutical, health, and general front-shop products, delivers specialized pharma-logistic solutions, and manages customer loyalty initiatives. Established in 1978 and headquartered in Midrand, South Africa, Dis-Chem boasts a substantial presence with 289 stores spread across all nine South African provinces, supplemented by four outlets in Namibia and two in Botswana.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
ZAc3,238.00 -12.00 (-0.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.29
Float Shares
545.64M
Free Float %
63.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-7.80% -6.25% -4.19% -5.49% +0.52% -0.09% +4.17% +59.03% +14.77% +62.80% +62.80%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
3,238.00
DCF (Unlevered) 3,372.92 +4.2%
DCF (Levered) 1,048.77 -67.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 38% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 2 -2
Hold 4 0
Sell 0 0
Strong Sell 1 0
Quality scores
Altman Z-Score
6.16
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +9.3% ★ Q1'26: +17.0% (vs Q1'24)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -17.4% Q1'26: -28.6% (vs Q1'24)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +2.9% ★ Q1'26: -1.2% (vs Q1'24)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +4.7% Q1'26: +3.4% (vs Q1'24)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +12.5% ★ Q1'26: +18.7% (vs Q1'24)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    0.0% ★ Q1'26: -0.1% (vs Q1'24)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    2.04× Q1'26: 1.18× (vs Q1'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.61) × ERP
WACC = 82% × Ke + 18% × Kd (10.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 3,372.92 Current price: 3,238.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Feb 2017
actual 		Feb 2018
actual 		Feb 2019
actual 		Feb 2020
actual 		Feb 2021
actual 		Feb 2022
actual 		Feb 2023
actual 		Feb 2024
actual 		Feb 2025
actual 		Feb 2026
8 Rev. Ana.
5 EPS Ana. 		Feb 2027
8 Rev. Ana.
5 EPS Ana. 		Feb 2028
7 Rev. Ana.
4 EPS Ana.
Revenue
17.27B
est: 17.63B (-2.0%)
19.56B
est: 19.95B (-2.0%)
21.42B
est: 21.45B (-0.2%)
23.98B
est: 23.95B (+0.1%)
26.28B
est: 26.47B (-0.7%)
30.41B
est: 30.49B (-0.3%)
32.66B
est: 32.56B (+0.3%)
36.28B
est: 36.18B (+0.3%)
39.17B
est: 39.10B (+0.2%)
42.88B
42.53B – 43.25B
+9.7% YoY
47.15B
45.83B – 48.09B
+10.0% YoY
51.55B
49.54B – 53.46B
+9.3% YoY
EBITDA
1.31B
est: 1.42B (-8.0%)
1.37B
est: 1.61B (-14.6%)
1.93B
est: 1.73B (+11.7%)
1.85B
est: 1.93B (-4.3%)
1.99B
est: 2.13B (-6.7%)
2.39B
est: 2.46B (-2.6%)
2.75B
est: 2.62B (+4.6%)
2.91B
est: 3.38B (-13.7%)
3.30B
est: 3.15B (+4.6%)
3.46B
3.43B – 3.49B
+9.7% YoY
3.80B
3.70B – 3.88B
+10.0% YoY
4.16B
4.00B – 4.31B
+9.3% YoY
EBIT
1.15B
est: 912.90M (+25.5%)
1.15B
est: 1.03B (+11.6%)
1.40B
est: 1.11B (+25.7%)
1.27B
est: 1.24B (+2.5%)
1.29B
est: 1.37B (-6.2%)
1.54B
est: 1.58B (-2.5%)
1.74B
est: 1.69B (+3.5%)
1.85B
est: 2.21B (-16.4%)
2.15B
est: 2.01B (+7.3%)
2.20B
2.18B – 2.22B
+9.7% YoY
2.42B
2.35B – 2.47B
+10.0% YoY
2.65B
2.54B – 2.74B
+9.3% YoY
Net Income
612.35M
est: 573.55M (+6.8%)
684.28M
est: 806.32M (-15.1%)
734.72M
est: 750.74M (-2.1%)
598.23M
est: 655.01M (-8.7%)
668.69M
est: 676.58M (-1.2%)
853.45M
est: 832.23M (+2.5%)
1.00B
est: 1.04B (-4.0%)
984.48M
est: 984.48M (+0.0%)
1.18B
est: 1.18B (+0.0%)
1.28B
1.15B – 1.36B
+8.6% YoY
1.49B
1.33B – 1.56B
+16.5% YoY
1.74B
1.47B – 1.91B
+16.7% YoY
SGA
3.45B
est: 997.81M (+245.3%)
4.11B
est: 1.13B (+264.0%)
3.45B
est: 1.21B (+184.0%)
4.05B
est: 1.36B (+198.7%)
4.96B
est: 1.50B (+231.3%)
572.39M
est: 1.73B (-66.8%)
789.91M
est: 1.84B (-57.1%)
953.90M
est: 2.05B (-53.4%)
972.01M
est: 2.55B (-61.9%)
2.80B
2.78B – 2.82B
+9.7% YoY
3.08B
2.99B – 3.14B
+10.0% YoY
3.37B
3.23B – 3.49B
+9.3% YoY
EPS
0.75
est: 0.67 (+12.2%)
0.80
est: 0.94 (-14.9%)
0.85
est: 0.87 (-2.8%)
0.70
est: 0.76 (-8.3%)
0.78
est: 0.79 (-1.1%)
0.99
est: 0.97 (+2.1%)
1.16
est: 1.21 (-4.5%)
1.15
est: 1.13 (+1.8%)
1.38
est: 1.34 (+3.2%)
1.42
1.34 – 1.58
+5.9% YoY
1.67
1.55 – 1.82
+17.8% YoY
1.93
1.72 – 2.23
+15.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-28 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-27 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-26 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-25 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-22 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-21 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-20 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-19 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-18 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-15 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-14 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-13 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-12 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-11 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-08 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-07 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-06 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-05-05 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-05-04 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-04-30 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-04-29 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-04-28 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-04-24 B+ 3/5 3/5 5/5 5/5 1/5 3/5 2/5
2026-04-23 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-04-22 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-04-21 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-04-20 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-04-17 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5
2026-04-16 B+ 3/5 3/5 5/5 5/5 1/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.88B
OE per share TTM
3.35
Owner's Yield
9.60%
Maintenance CapEx ratio
65.83%
Maint CapEx / Avg PPE
13.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 60 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L 0.11% 50.2K 0.54%
2 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.11% 132.2K 0.42%
3 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.07% 404.3K 0.55%
4 WisdomTree Emerging Markets SmallCap Dividend Fund DGS 0.07% 1.18M 0.58%
5 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.06% 234.1K 0.72%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.05% 184.1K 0.74%
7 iShares Ageing Population UCITS ETF AGED.L 0.05% 435.0K 0.40%
8 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.03% 3.98M 0.06%
9 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.02% 144.4K 0.44%
10 Avantis Emerging Markets ex-China Equity ETF AVXC 0.02% 84.7K 0.33%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
99.7K
Shares Outstanding
856.97M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Stanley Richard Nathaneal Goetsch Executive Director 18M male
Ivan Leon Saltzman Executive Director 18M male
Rui Manuel Morais Chief Executive Officer & Executive Director 16M male
Julia Pope Chief Financial Officer & Executive Director 8M female
C. A. Swanepoel Prescribed Officer 5M —
Christopher J. Williams Prescribed Officer 5M —
T. J. Ponter Prescribed Officer 5M —
Nikki Lumley Company Secretary — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals